A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
Andrew M SkinnerXing TanBenjamin D SirbuLarry H DanzigerDale N GerdingStuart JohnsonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.